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Abstract
Evidence is presented for the nuclear presence of a functional heteromeric complex of epidermal growth factor (EGFR), Src
and the Signal Transducer and Activator of Transcription (Stat)3 proteins in pancreatic cancer cells. Stat3 remains nuclear
and associated with Src or EGFR, respectively, upon the siRNA knockdown of EGFR or Src, demonstrating the resistance of
the complex to the modulation of EGFR or Src alone. Significantly, chromatin immunoprecipitation (ChIP) analyses reveal
the nuclear EGFR, Src and Stat3 complex is bound to the c-Myc promoter. The siRNA knockdown of EGFR or Src, or the
pharmacological inhibition of Stat3 activity only marginally suppressed c-Myc expression. By contrast, the concurrent
modulation of Stat3 and EGFR, or Stat3 and Src, or EGFR and Src strongly suppressed c-Myc expression, demonstrating that
the novel nuclear heteromeric complex intricately regulates the c-Myc gene. The prevalence of the transcriptionally
functional EGFR, Src, and Stat3 nuclear complex provides an additional and novel mechanism for supporting the pancreatic
cancer phenotype and explains in part the insensitivity of pancreatic cancer cells to the inhibition of EGFR, Src or Stat3
alone.
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Introduction
Many intracellular biochemical processes are triggered by the
assembly of proteins into macromolecular complexes. The
association between proteins or of proteins with other molecular
entities modulates protein conformation, providing a means to
regulate the myriad of biochemical processes that serve to efficiently
manage vital biological responses. Protein dynamics and trafficking,
and protein stability are also processes that can be modulated by the
association of proteins with others. In the broader sense, inter-
molecular associations allow specialty proteins, such as receptors,
adapters, enzymes, and transcription factors to differentially
modulate intracellular events, thereby creating the diversity in
physiological responses and promoting context dependency.
During the induction of signal transduction, there is assembly of
different proteins, each of which has specific functions important
for the signal transduction and the accompanying biological
response. The traditional epidermal growth factor receptor
(EGFR) signal transduction pathway incorporates the activation
of the mitogen-activated protein kinase kinase (MEK)-mitogen-
activated protein kinase/extracellular signal-regulated kinase
(ErkMAPK) and promotes mitogenic responses [1,2]. The EGFR
induction also promotes the activation of the Signal Transducer
and Activator of Transcription (STAT) family of proteins, which
similarly have a central role in EGF-induced biological responses
[1]. The STAT proteins are latent cytoplasmic transcription
factors that are activated in response to cellular stimulation by
cytokines and growth factors [3] via the phosphorylation of a
critical tyrosyl residue (Tyr705 for Stat3). The tyrosine phosphor-
ylation of STATs is mediated by tyrosine kinases of growth factor
receptors and by cytoplasmic tyrosine kinases, such as Src and
Janus kinase (Jaks) families. Activated STATs as dimers in the
nucleus bind to specific DNA response elements in the promoters
of target genes to induce gene transcription. The nuclear
translocation mechanism for STATs has been the subject of
recent intense investigation. Stat3 nuclear translocation has been
reported to be mediated by the recognition and transport by
importin-a and the Ran-GTPase [4], and by mechanisms
involving the chaperoning by MgcRacGAP [5], EGF receptor-
mediated endocytosis [6], and by plasma membrane-associated
lipid rafts trafficking [7].
The prevalence of many hyperactive signal transduction
pathways that support the cancer phenotype is a major challenge
to therapy. Further to the classical way of promoting crosstalks
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among multiple signaling pathways, macro-molecular protein
assemblies provide additional unique mechanisms for inducing
events that would support the malignant phenotype. Such a non-
traditional signaling mechanism has been identified for the EGFR,
which has been detected in the cell nucleus and observed to
function as a transcription factor [8,9]. Studies further revealed the
nuclear EGFR complexes with Stat3 in breast cancer cells, and
this complex induces specific genes, including the inducible nitric
oxide synthase (iNOS) [10]. The additional EGFR function would
compound its role as a mitogen and a promoter of cell survival,
which all favor cancer. In that regard, the concurrent aberrant
activation of EGFR and downstream signal mediators, including
Src and Stat3, which occur with high frequencies in human
cancers reflects an overall signaling complexity that supports the
cancer phenotype. For example, with reference to pancreatic
cancer, aberrant activation of EGFR occurs in 30–50% of cases
[11], activated c-Src is noted in more than 70% of cases, and
frequently accompanies EGFR overexpression [12], while aber-
rant Stat3 activation is also highly prevalent [13,14,15]. Impor-
tantly, our recent report that pancreatic cancer is more sensitive to
the concurrent inhibition of aberrant Stat3 and EGFR or Src [16]
shows the utilization of multiple aberrant signaling pathways for
the maintenance of the cancer phenotype and how this influences
the responsiveness to therapy. To extend our earlier studies [16],
we sought to probe the molecular and functional interplay
between Stat3, EGFR and Src and the underlying mechanisms
of support of the pancreatic cancer phenotype. We herein provide
evidence for a functional nuclear heteromeric EGFR, Src and
Stat3 complex in pancreatic cancer cells, which promotes the
induction of the c-Myc gene. Our report is the first on the
identification of a nuclear EGFR, Src and Stat3 heteromeric
complex that promotes the c-Myc gene induction. Understanding
the dynamics of the EGFR, Src and Stat3 molecular interactions
in pancreatic cancer would provide basis to design novel effective
multiple-targeted therapy approaches for pancreatic cancer.
Materials and Methods
Cells and Reagents
The human pancreatic cancer, Panc-1 and Colo-357 lines have
all been previously described [16,17]. The immortalized human
pancreatic duct epithelial cell (HPDEC) line was a kind gift of Dr.
Tsao, OCI, UHN-PMH, Toronto) [18]. HPDEC were grown in
Keratinocyte-SFM media supplemented with 0.2 ng EGF, 30 mg/
mL bovine pituitary extract and containing antimycol. All other
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing 5% iron-supplemented bovine calf serum and 100
units/ml penicillin-streptomycin.
Peptide synthesis
The Stat3 SH2 domain peptide inhibitor (SPI), FISKERER-
AILSTKPPGTFLLRFSESSK, the EGFR peptide motifs, pY1068
EGFR (pY1068), PEpYINQS and the pY1086EGFR (pY1086),
PVpYHNQPwere purchased from Peptide 2.0 (Fairfax, VA) at.95%
purity.
Nuclear Extract Preparation and Gel Shift Assays
Nuclear extract preparation from cells was carried out as
previously described [17].
Sub-cellular fractionation, and SDS-PAGE/Western Blot
Analysis
Western blotting analysis was performed as previously described
[19,20] on whole-cell lysates, and on cytosolic and membrane
fractions, and on nuclear extracts. Sub-cellular fractions were
prepared according standard protocol. Briefly, cells were washed
using PBS, resuspended and lysed in low-salt buffer (20 mM
HEPES (pH 7.9), 1 mM EDTA, 1 mM EGTA, 20 mM NaF,
1 mM Na3VO4, 1 mM Na4P2O7, 1 mM dithiothreitol, 1 mM
TLA, 0.5 mM phenylmethylsulfonyl fluoride and 0.5% Nonidet P-
40), and centrifuged (13,000 x g, 4uC, 30 s) to obtain the cytosolic
fraction. The pellet was washed three times with phosphate-
buffered saline (PBS), resuspended in high-salt buffer (420 mM
NaCl, 20 mM HEPES (pH 7.9), 1 mM EDTA, 1 mM EGTA,
20% Glycerol, 20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7,
1 mM dithiothreitol, 1 mM TLA and 0.5 mM phenylmethylsul-
fonyl fluoride), incubated at 4uC for 30 min, with rocking, and
centrifuged at (13,000 x g, 4uC, 30 min) to obtain the nuclear
fraction (supernatant). The pellet obtained was washed three times
with PBS, resuspended in RIPA lysis buffer (50 mM Tris (pH 7.4),
150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 0.1% SDS,
1 mM TLA, and 0.5 mM phenylmethylsulfonyl fluoride), incu-
bated for 30 min at 4uC with rocking, and centrifuged (13,000 x g,
4uC, 20 min). The supernatant was collected as the membrane
fraction. Primary antibodies used are against pY845EGFR
(Upstate Biotech, Millipore, Billerica, MA), pY705Stat3, Stat3,
pY1068EGFR, pY1086EGFR, pY1173EGFR, EGFR, pY416Src,
Src, and b-Actin (Cell Signaling Technology, Danvers, MA), and
Tata-binding protein (TBP) (Santa Cruz Biotechnology, Santa
Cruz, CA). The blocking peptides were purchased from the
respective companies.
Small-interfering RNA (siRNA) Transfection
siRNA sequences for EGFR and Src were ordered from
Dharmacon RNAi Technologies, Thermo Scientific (Lafayette,
CO). Sequences used are: EGFR sense strand, 59-GAAGGAAACU-
GAAUUCAAAUU-39; EGFR antisense strand, 59-pUUUGAAUU-
CAGUUUCCUUCUU-39; control siRNA sense strand, 59-AGUAA-
UACAACGGUAAAGAUU-39; and control siRNA antisense strand,
59-pUCUUUACCGUUGUAUUACUUU-39. The c-Src SMART-
pool siRNA reagent (NM-005417, Catalog # M-003175-01-05) was
used for Src. Transfection into cells was performed using 20 nM of
EGFR siRNA or 25 nM of Src siRNA and 8 ml Lipofectamine
RNAiMAX (Invitrogen Corporation, Carlsbad, CA) in OPTI-MEM
culture medium (GIBCO, Invitrogen Corporation).
Immunoprecipitation (IP), and Sequential
Immunoprecipitation Studies
These studies were performed as previously reported [21] using
whole-cell lysates or nuclear extracts (250 mg total protein) and
5 mL of anti-EGFR or anti-Src polyclonal antibody or the
monoclonal anti-Stat3 antibody (Cell Signaling Technology). For
specificity, immunoblotting analysis using anti-EGFR, anti-Src
and anti-Stat3 antibody was performed in the presence of the
respective blocking peptide. Sequential IP studies were performed
according to published procedures [10] with some modifications as
follows: nuclear extracts, prepared as previously described [21],
were subjected to a similar immunoprecipitation with respect to
the first primary antibody, anti-EGFR antibody (Cell Signaling) or
IgG (Santa Cruz) at 4uC overnight. The immunecomplex was then
pelleted with 20 mL protein A/G agarose beads (Santa Cruz),
washed three times using wash buffer A (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0), and then two
times with wash buffer B (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 500 mM NaCl, 20 mM Tris-HCl, pH 8.0). Then the
proteins were eluted with freshly prepared elution buffer (1% SDS,
100 mM NaHCO3) and subjected to the second immunoprecip-
itation by incubating with anti-Src antibody or IgG (Santa Cruz).
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The complexes were then precipitated, washed, eluted with lamelli
buffer and then subjected to SDS-PAGE and Western blotting
analysis probing for Stat3.
Immunostaining with laser-scanning confocal imaging
Panc-1 cells growing on coverslips in 12-well plates were treated
with or without inhibitors for 1 or 24 h and subjected to
immunostaining and fluorescence or laser-scanning confocal
microscopy, as previously described [21]. Cells were fixed with
4% paraformaldehyde for 15 min, washed three times with PBS,
permeabilized with 0.25% Triton X-100 for 10 min, and washed
three times with PBS. Specimens were then blocked in 0.1% BSA
in PBST for 30 min and incubated overnight at 4uC with rat
monoclonal anti-EGFR (Santa Cruz), mouse monoclonal anti-Src
(Cell Signaling), and rabbit polyclonal anti-Stat3 (Cell Signaling)
antibodies at 1:50 dilution (in 0.1% BSA). Subsequently, cells were
rinsed three times in PBST, incubated for 1 h at room
temperature in the dark with 1:1000 dilutions of the three
AlexFluor secondary antibodies, ALexaFLuor405 (goat anti-
mouse), AlexaFluor488 (donkey anti-rabbit) and AlexaFluor546
(goat anti-rat) (Molecular Probes, Invitrogen) for EGFR, Src and
Stat3 detection, respectively. Specimens were then washed three
with PBST. Subsequently, coverslips were removed and mounted
on slides using Fluoromount-G (Southern Biotech, Birmingham,
AL) and prevented from drying by sealing the edges with nail
paint. Slides were stored in the dark at 4uC until images were
captured. For negative staining, secondary antibodies were added
without the primary antibodies. Confocal analysis was performed
by the examination of slides under Leica TCS SP5 confocal
microscope (Germany) at appropriate wavelengths. Images were
captured and processed using the Leica TCS SP 5 software.
Chromatin Immunoprecipitation (ChIP) and Sequential
ChIP Analyses
For ChIP assay, cells in culture were treated with formaldehyde at
a final concentration of 1%, for 10 min at room temperature followed
by treatment with glycine at a final concentration of 0.125 M for
5 min at room temperature for cross-linking. Subsequently, cells were
washed with ice-cold PBS and resuspended in and lysed with lysis
buffer (20 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM EGTA,
1 mMNaF, 1 mMNa3VO4, 1 mMNa4P2O7, 1 mM dithiothreitol),
1X TLA, 1 mM phenylmethylsulfonyl fluoride, 5% Nonidet P-40,
and centrifuged. Then nuclear pellet was resuspended in nuclei lysis
buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS and
protease inhibitors) (Roche, Indianapolis, IN). The nuclear lysates
were sonicated (Omni International, Kennesaw, GA) at 30% power
for 3 pulses for 10 s intervals on ice to shear DNA. The chromatin
solution was pre-cleared with protein A/G agarose beads (Santa
Cruz) for 1 h at 4uC with rocking. Then the pre-cleared lysates were
immunoprecipitated by incubating with anti-EGFR, anti-Src, or anti-
Stat3 antibodies or with IgG (for no antibody) (Santa Cruz) at 4uC
overnight with rocking. The complexes were collected with 20 mL
protein A/G agarose beads (Santa Cruz), washed three times using
wash buffer A (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris-HCl, pH 8.0) and two times with wash buffer B (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl,
pH 8.0). Then complexes were eluted with freshly prepared elution
buffer (1% SDS, 100 mM NaHCO3). Cross-links were reversed by
heating at 65uC in the presence of NaCl followed by proteinase K
treatment (20 ml of a 20 mg/ml) for 6 h. The DNA was recovered
and purified using DNA purification kit from Qiagen (Valencia, CA).
The purified chromatin immunoprecipitated DNAwas next used as a
template for the polymerase chain reaction (PCR) amplification of the
c-Myc promoter using the primers, Forward, 59AAAAGGGGAAA-
GAGGACCTGG-39, and Reverse, 59-TAAAAGGGGCAAGTG-
GAGAGC-39 or the TWIST promoter using the primers, Forward,
59- AGTCTCCTCCGACCGCTTCCTG -39.
Reverse: 59- CTCCGTGCAGGCGGAAAGTTTGG -39 (In-
vitrogen). The PCR products, 133 bp for c-Myc and the 332-bp
for TWIST [22] were resolved on 2% agarose gel. The sequential
ChIP studies were performed as previously reported [10] and
following the sequential immunoprecipitation studies described,
using the first primary antibody (anti-EGFR) and the second
primary antibody (anti-Src). The recovered complexes after the
secondary immunoprecipitation were eluted with the elution
buffer and then subjected to ChIP assay, as described.
Gel filtration chromatography
The pre-packed Superdex 200 10/30 GL glass column was
purchased from GE Healthcare Life Sciences (Piscataway, NJ). The
chromatography system used in the study was the BioLogic
Duoflow System (Bio-Rad, Hercules, CA). The chromatography
analysis was performed following the manufacturer’s instructions
with a general run sequence of equilibration, load, elution,
regeneration and storage. RIPA Buffer (50 mM Tris, pH 7.4,
150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Nonidet P-40) was
used as the mobile phase buffer. Samples (Panc-1 cell lysate, 2 mg
total protein in a volume of 250 ml) were loaded unto the column,
then flow rate was adjusted to 0.25 ml/min, and then fraction
(500 ml) collection was initiated right after the sample loading and
monitored by the eluent absorbance at 280 nm. According to the
absorbance peaks, fractions 21–34 were selected and subjected to
immunoblotting analysis using antibodies against EGFR, Stat3, and
Src (Cell Signaling), and against RNA helicase A (RHA) (Abcam,
Cambridge, MA). For immunoprecipitation assay, 100 ml each of
fractions 23–27 were pooled, from which EGFR immunecomplex
was precipitated using anti-EGFR antibody (Cell Signaling) and
subjected to immunoblotting analysis for Stat3, Src and EGFR.
Preparation of anti-EGFR and mouse IgG1-GNP probes
Gold nanoparticles (GNPs), 0.1 nM, with a diameter of 40 nm
were purchased from Ted Pella Inc. (Redding, CA). Mouse
monoclonal anti-EGFR [F4] antibody was purchased from Abcam
(cat. no. ab62, conc. 1.2 mg/ml), and non-specific mouse mono-
clonal IgG1 was purchased from Sigma (cat. no. M9629, conc.
1 mg/ml). Polyclonal anti-Stat3 (conc. 0.2 mg/ml), polyclonal anti-
Src (0.1 mg/ml), polyclonal anti-EGFR (0.2 mg/ml) and non-
specific rabbit IgG (0.4 mg/ml) were purchased from Santa Cruz.
All other chemicals and buffer ingredients for the assay development
were purchased from Sigma. The anti-EGFR-GNP probe was
prepared by adding 10 ml of mouse monoclonal anti-EGFR
antibody to 1 ml of GNPs. After incubation for 15 min at room
temperature, the probe was blocked with 2.5 mg BSA for 30 min.
After the centrifugation at 10,000 rpm for 5 min, the supernatant
was discarded and the nanoparticle residue was redispersed in
0.5 ml of 0.25% BSA in 10 mM phosphate buffer (PB). The probe
was then used in the assay. The negative control mouse IgG1-GNP
probe was prepared by adding 10 ml of mouse monoclonal IgG1
antibody to 1 ml GNPs, and following the procedure identical to the
one used for the EGFR probe preparation. Mouse IgG1 was used
here to prepare the control probe, because the anti-EGFR
monoclonal antibody is a mouse IgG1 type antibody.
Detection and kinetic binding study of EGFR from
nuclear extract to the GNP probes
The Panc-1 nuclear extract sample was diluted in phosphate
buffer (PB) to 1 mg/ml of total protein. In a sample cell for
A Functional Nuclear EGFR, Src and Stat3 Complex
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Dynamic Light Scattering (DLS) measurement (Hellma cuvette
QS 3 mm), 20 ml of the anti-EGFR-GNP probe was mixed with
2 ml of the sample, and the particle size increase was read with a
DLS instrument (Zetasizer Nano ZS90 DLS system, Malvern
Instruments Ltd, England) at exactly 1, 6, 11, 16, and 30 min after
the mixing. The same experiment was also performed using the
mouse IgG1-GNP probe. In order to confirm the specificity of the
anti-EGFR-GNP probe in the detection of EGFR from nuclear
extract, an inhibition experiment was conducted by treating 5 ml
of the sample with 1 ml of monoclonal anti-EGFR antibody at
room temperature for 7 min and 24 min prior to using the sample
in the assay. After this incubation, 20 ml of the anti-EGFR-GNP
probe was mixed with 2 ml of the treated sample, and the particle
size was read at 1, 6 and 11 min after the mixing.
Protein complex binding partner study using polyclonal
antibody
In a 1.5 ml microcentrifuge tube, 80 ml of the anti-EGFRGNP
probe was mixed with 8 ml of the sample. After incubation for
30 min at room temperature, this solution was divided into four
20 ml portions. After transferring into the sample cell, the particle
size of each of these portions was read with a DLS instrument.
After this reading, the solution was spiked with a polyclonal
antibody: either with 1 ml of anti-Stat3 or 2 ml of anti-Src or 1 ml of
anti-EGFR or 0.5 ml of rabbit IgG. The particle size increase was
read at exactly 5 min and 10 min after the start of the first
reading.
Dynamic Light Scattering (DLS) measurements
The DLS measurements of all sample solutions were conducted
using a Zetasizer Nano ZS90 DLS system equipped with a red
(633 nm) laser and an Avalanche photodiode detector (APD)
(quantum efficiency.50% at 633 nm) (Malvern Instruments Ltd).
DTS applications 5.10 software was used to analyze the data. The
average particle size (Z-average) of the solution was obtained using
a Cumulant method. For each sample, ten DLS measurements
were conducted with one run, and each run lasted for 10 seconds.
All measurements were done at a 90u detection angle.
Results
Detection of nuclear EGFR, Src and Stat3 heterocomplex
We sought to investigate the signaling complex assembly and
the dynamics of the interactions of the hyperactive Stat3, EGFR
and Src [14,16,23] within the context of the human pancreatic
cancer phenotype. Co-immunoprecipitation (co-IP) with immu-
noblotting analysis shows, EGFR immunecomplex from Panc-1 or
Colo-357 whole-cell lysates contained both Src and Stat3
(Fig. 1A(i)), Src immunecomplex contained both EGFR and Stat3
(Fig. 1A(ii)), while Stat3 immunoprecipitate contained EGFR and
Src (Fig. 1A(iii)). For specificity, the non-specific rabbit IgG in the
immunoprecipitation and immunoblotting analysis for Src, Stat3
or EGFR showed no detectable protein (Fig. 1A, IgG, and data
not shown), and the immunoblotting analysis performed on the
immune precipitates in the presence of the respective blocking
peptides (BP) showed a complete or near complete block of the
immune detection of Stat3, Src or EGFR, compared to the levels
detected in the absence of the blocking peptides (Fig. 1B(i)-(iii),
compare + BP, lower panels to - BP, upper panels). We
determined the effect of siRNA knockdown of EGFR or Src on
the complex formation. Co-immunoprecipitation with immuno-
blotting studies of whole-cell lysates from Panc-1 cells showed that
when EGFR is knockdown by siRNA (Fig.1C(i), upper band), Src
immunecomplex remains associated with Stat3 (Fig. 1C(i), IP:Src),
and vice-versa (Fig. 1C(i), IP:Stat3). Likewise, when Src is
knockdown by siRNA (Fig. 1C(ii), upper band), EGFR immune-
complex remains associated with Stat3 (Fig. 1C(ii), IP:EGFR), and
vice-versa (Fig. 1C(ii), IP:Stat3). Scrambled (con) siRNA has no
effect. These findings indicate that with respect to the EGFR, Src
and Stat3 heteromeric complex, Stat3 proteins remains associated
with Src or EGFR, respectively, upon the siRNA knockdown of
EGFR or Src.
We asked the question whether the observed EGFR, Src and
Stat3 heteromeric complex was present in the nucleus. Co-
immunoprecipitation with immunoblotting analysis of nuclear
extracts shows that EGFR immunecomplex contained both Stat3
and Src (Fig. 2A(i), IP:EGFR), Src immunecomplex contained
both Stat3 and EGFR (Fig. 2A(ii), IP:Src), while Stat3 immune-
complex contained both EGFR and Src (Fig. 2A(iii), IP:Stat3).
These data demonstrated the presence of the EGFR, Src and
Stat3 heteromeric complex in the nucleus. For specificity of the
immunoreagents, the non-specific rabbit IgG pull-down samples
that were similarly immunoblotted showed no detectable EGFR,
Src or Stat3 (Fig. 2A, IgG and data not shown). Immunoblotting
analysis probing for the Tata-binding protein (TBP) confirmed
that the extracts used in these studies are of nuclear origin
(Fig. 2A(iv)). The heteromeric complex was validated by
performing sequential immunoprecipitation analysis, whereby
EGFR immunecomplex (IP:EGFR) was further subjected to a
secondary immunoprecipitation using anti-Src antibody
(IP:EGFR/IP:Src) and then immunoblotted for EGFR and Stat3.
The results of these studies showed the presence of EGFR and
Stat3 in the sequential immunoprecipitates (Fig. 2B, IP:EGFR/
IP:Src). By contrast, IgG pull-down that was subjected to
immunoblotting for EGFR or Stat3 showed no detectable levels
(Fig. 2B, IgG), further confirming the specificity of the immunor-
eagents used.
The presence of the EGFR, Src and Stat3 complex in the
nucleus of pancreatic cancer cells was further investigated by
subjecting nuclear extract preparations to gel filtration column
chromatography analysis (Superdex200, exclusion limit 200 kD),
as described in ‘‘Materials and Methods’’, in conjunction with
immunoblotting analysis. The collected fractions, which showed
peak absorbance at 280 nm (data not shown) were immuno-
probed. Results showed that the EGFR protein first appears in the
fraction 23 and is present together with Stat3 and Src, and the
three proteins are concurrently detected in the fractions 23–29
(Fig. S1A). Results also showed detectable Stat3 and Src proteins
in fractions 30 through 32 well after EGFR was completely eluted
(Fig. S1A). Analysis of the previously-reported EGFR protein
partner, RNA helicase A (RHA) [24] also showed detectable levels
that were predominantly in the fractions 23 and 24 (Fig. S1A,
RHA). These fractions were further subjected to co-immunopre-
cipitation analysis to validate the presence of the complex.
Immunoblotting analysis of EGFR immunecomplex prepared
from the pooled fractions 23–27 further showed the presence of
Src and Stat3 (Fig. S1B). The early and the concurrent elution of
EGFR, Src and Stat3 raise the possibility that each of the proteins
is part of a higher molecular weight protein complex, and also that
the three proteins associate as part of the same complex, as
suggested by the immunecomplex formation. There has been a
previous report about nuclear EGFR/Stat3 complex under
conditions of cellular stimulation by EGF [10]. We therefore
investigated whether the nuclear EGFR, Src, Stat3 complex was
present constitutively (without ligand stimulation) in tumor cells.
Immunoblotting analysis did not detect any appreciable levels of
Stat3 or Src in EGFR immunecomplex or of Src or EGFR in
Stat3 immunoprecipitate from the nuclear extracts prepared from
A Functional Nuclear EGFR, Src and Stat3 Complex
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human breast cancer, MDA-MB-231 and the human non-small
cell lung cancer, A549 lines (Fig. S1C), suggesting a minimal
possibility of the existence of a constitutive nuclear EGFR, Src,
Stat3 complex in the two cancer cell types. These studies together
show for the first time that EGFR, Src and Stat3 form a
heteromeric complex in the nucleus of pancreatic cancer cells.
Given the detection of the EGFR, Src and Stat3 complex in
whole-cell and nuclear lysates, we were interested to determine the
relative levels and the sizes of EGFR, Src and Stat3 in the different
sub-cellular fractions. Membrane and cytosolic fractions, and
nuclear extracts were prepared from Panc-1 cells according to
established protocols and which involved using 10% Nonidet P-40
lysis, and a low-salt HEPES buffer extraction for cytosolic extract,
a high-salt HEPES buffer extraction for nuclear extracts (18, 22),
and 0.5% SDS buffer for the membrane fraction. Immunoblotting
analysis of samples of equal total protein from the sub-cellular
fractions shows that with respect to each of the EGFR, Src, or
Stat3 protein, the size is the same in the membrane (Mem),
cytosolic (Cyto), or nuclear fraction (Nuc) (Fig. 2C). Results further
show that the level of the total EGFR protein is highest in the
membrane, and is higher in the cytosolic fraction than in the
nuclear extract (Fig. 2C (i)). By contrast, results show that Stat3
levels are highest in the cytosolic fraction, and higher in the
nuclear extract, compared to the levels associated with the cell
membrane (Fig. 2C(ii)). The results for Src also showed noticeable
differences, with the membrane-associated levels higher than both
the cytosolic and nuclear levels, which were nearly identical
(Fig. 2C(iii)). Significantly, the non-denaturing conditions (10%
Nonidet P-40, low- or high-salt extraction) for preparing the
cytosolic and nuclear extracts raises the potential that the EGFR
protein detected in the cytosolic compartment and in the nucleus is
a soluble form, and further that the Stat3 protein in the cytosolic
fraction and in the nucleus is potentially a dimer. Moreover, this is
the first report of the nuclear presence of c-Src tyrosine kinase in
cancer cells.
The role of EGFR and Src tyrosine kinases in the nuclear
EGFR, Src and Stat3 heterocomplex formation
We determined the importance of EGFR or Src in the assembly
of the nuclear complex by examining the effect of siRNA
knockdown. Immunoblotting analysis of immunecomplexes of
Stat3 (IP:Stat3), EGFR (IP:EGFR) or Src (IP:Src) prepared from
nuclear extracts showed that the siRNA knockdown of Src
(Fig. 3A(i), upper panel) has little effect on the association of Stat3
with EGFR in the nucleus (Fig. 3A(i), IP:Stat3, IP:EGFR), while
similarly, the knockdown of EGFR (Fig. 3A(ii), upper panel) did
not alter the binding of Stat3 to Src (Fig. 3A(ii), IP:Stat3, IP:Src).
Scrambled (con) siRNA has no effect. Similar to the results for the
Figure 1. Co-immunoprecipitation with immunoblotting analysis of EGFR, Src and Stat3 association in Panc-1 and Colo-357 cells.
Immunoblotting analyses of immunecomplexes of EGFR (IP:EGFR), Src (IP:Src), and Stat3 (IP:Stat3), or of non-specific IgG non-immunoprecipitate
prepared from whole-cell lysates of Panc-1 or Colo-357 cells untransfected (A and B) or transfected with EGFR siRNA, Src siRNA, or control (con) siRNA
(C) and probing for Src, Stat3 and EGFR in the absence (A and C) or presence (B) of Stat3 blocking peptide (Stat3 BP), Src blocking peptide (Src BP) or
EGFR blocking peptide (EGFR BP). Bands corresponding to proteins in gel are shown; input: except where indicated, represents the immunoblotting
for the respective immunoprecipitated protein in the same amount of lysate used in the assay; Data are representative of 3 independent studies.
doi:10.1371/journal.pone.0019605.g001
A Functional Nuclear EGFR, Src and Stat3 Complex
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19605
whole-cell lysates analysis in Figure 1C, these data together
indicate that the knockdown of one protein does not preclude the
interaction between the other two protein partners.
We next sought to determine if the heteromeric complex
formation is dependent on the tyrosine kinase activities of EGFR
and Src. Compared to IgG, immunoblotting of immunecomplex
of EGFR showed no effect of 1 h-treatment of Panc-1 cells with
the selective EGFR inhibitor, Iressa (ZD1839, ZD), the Src
inhibitor, Dasatinib (Das), or the Stat3 dimerization disrupting
inhibitor, S3I-201 [25] (Fig. 1G, IP:EGFR, lanes 3, 6, and 8,
compared to lane 2). By contrast, immunoblotting analysis of
EGFR immunecomplex showed decreased levels of associated
Stat3 protein, but not Src, when cells were treated with ZD, Das,
or S3I-201 for 24 h (Fig. 3B, lanes 4, 7, and 9). These findings
together suggest the EGFR and Src kinase activities promote the
association of Stat3 with EGFR in the nuclear heteromeric
complex, while the inhibition of EGFR or Src kinase alone does
not preclude the interaction between EGFR and Src. Further-
more, the Stat3 dimerization disrupting inhibitor blocks Stat3
association in the complex; however, the disruption of Stat3
dimerization, and hence its binding to EGFR does not preclude
EGFR interaction with Src. The observation that the nuclear
heteromeric EGFR, Src, and Stat3 complex was not completely
dissociated and that EGFR/Src complex persisted by 24-h
inhibition of EGFR (ZD) or Src (Das) (Fig. 3B, lanes 4, and 9)
has important clinical implications in regard to the responsiveness
of pancreatic cancer cells to a monotherapy targeting EGFR or
Src.
During the stimulation of the EGFR signaling pathway, key
phospho-tyrosine (pY) peptide motifs are induced, which recruit
different signaling proteins, including Stat3 [26,27]. The Stat3
SH2 domain binds to the receptor pY motifs through pY-SH2
domain interactions [28]. We therefore sought to probe further the
observed nuclear complex of the EGFR, Src and Stat3 with
respect to the peptide motifs potentially involved in the
interactions by using the known Stat3-binding EGFR motifs,
pY1068 peptide and pY1086 peptide, and the newly reported
Stat3 peptide inhibitor, SPI, which is derived from the Stat3 SH2
domain and is capable of blocking the binding of the Stat3 SH2
domain to pY peptide motifs [29]. Immunoblotting analysis of
Stat3 immunoprecipitates from nuclear extracts that have been
pre-incubated with the three peptides for 2 h at room temperature
showed no detectable EGFR protein (Fig. 3C(i)). These results
suggest the EGFR-Stat3 interaction is promoted by pY1068EGFR
and pY1086EGFR, and also that in binding to EGFR, Stat3
utilizes the key amino acid residues, 588–615 of its SH2 domain,
which make up the peptide inhibitor SPI [29]. By contrast, similar
probing with the SPI peptide showed no significant effect on the
immuno-detection of Src protein within the Stat3 immunecom-
plex (Fig. 3C(ii)), suggesting the direct interaction between Src and
Stat3 is independent of the amino acid residues 588–615 of the
Stat3 SH2 domain.
Figure 2. Co-immunoprecipitation with immunoblotting analysis of EGFR, Src and Stat3 complex in the nucleus and the sub-
cellular distribution of EGFR, Src and Stat3. (A and B) Immunoblotting analyses of immunecomplexes of EGFR (IP:EGFR), Src (IP:Src), Stat3
(IP:Stat3), EGFR/Src (IP:EGFR/IP:Src), or of non-specific IgG non-immuneprecpitate prepared from nuclear extracts of Panc-1 or Colo-357 cells and
probing for Stat3, EGFR, Src, or the Tata-binding protein (TBP); and (C), immunoblotting analysis of membrane (mem) and cytosolic (cyto) fractions
and of nuclear (nuc) extracts from Panc-1 cells probing for (i) EGFR, (ii) Stat3 and (iii) Src. Bands corresponding to proteins in gel are shown; input:
except where indicated, represents the immunoblotting for the respective immunoprecipitated protein in the same amount of nuclear extract used
in the assay; IP:EGFR/IP:Src, sequential immunoprecipitation with anti-EGFR and then anti-Src antibody; Data are representative of 3 independent
studies.
doi:10.1371/journal.pone.0019605.g002
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Nuclear EGFR, Src and Stat3 heterocomplex is
independent of EGFR-mediated endocytosis
We were interested to determine how the known nuclear
translocation mechanisms might affect the nuclear presence of
the heteromeric EGFR, Src and Stat3 complex. Several
mechanisms have been reported for EGFR nuclear translocation,
including receptor endocytosis, endosomal sorting machinery,
importins alpha1/beta1, and exportin CRM1 [30,31]. Previous
studies have also shown that Stat3 nuclear translocation is
facilitated by EGFR-mediated endocytosis [6]. However, the
siRNA knockdown of EGFR did not affect the nuclear presence
of Src/Stat3 (Fig. 3A(ii)), suggesting EGFR-mediated mechanisms
may not be utilized for the nuclear localization of Stat3 or Src.
To further determine whether endocytosis is required for the
nuclear presence of the heteromeric complex, cells were treated
with the pharmacological inhibitor of endocytosis, phenylarsine
oxide [6]. In contrast to PAO-induced inhibition of nuclear Stat3
DNA-binding activity induced by EGF [6], immunoblotting
analysis showed treatment with PAO has no effect on the nuclear
presence of EGFR, Src and Stat3 heterocomplex in pancreatic
cancer cells (Fig. 3D), suggesting the nuclear presence of the
heteromeric complex is not dependent on endocytosis. Altogeth-
er, these findings show that EGFR, Src and Stat3 associate into a
complex in a manner where all three proteins interact. However,
our study does not exclude the possibility that other proteins
could be present in the complex.
Detection and Analysis of the EGFR, Src and Stat3
heterocomplex through Nanoparticle Sizing (DANS)
technology with Dynamic Light Scattering
The EGFR, Src and Stat3 association was further probed using
DANS (Detection and Analysis through Nanoparticle Sizing)
technology [32,33,34,35,36,37]. The principle of DANS technology
for protein complex detection and binding partner analysis is a
single-step solution immunoassay based on gold nanoparticle (GNP)
immunoprobes coupled with dynamic light scattering (DLS)
detection. Details of this technology are provided in ‘‘Text S1’’
and illustrated in Fig. S2. Based on this general principle, the assay is
designed to detect and identify protein binding partners of a protein
complex. The kinetic binding assay revealed and confirmed that the
anti-EGFR-GNP probe detects EGFR from the sample specifically
(Fig. 4A(i)). The increase in particle size obtained with the anti-
EGFR-GNP probe was much larger than the one obtained with the
non-specific mouse IgG1 control probe (Fig. 4A(i)). The approxi-
mate net increase of the average nanoparticle size of the assay
solution was about 70 nm, after deducting the size increase caused
by non-specific interactions. For the mouse IgG1-GNP probe, the
particle size increase was less than 10 nm after incubation with the
sample for 30 min. Furthermore, the steepness of the kinetic curve
for the EGFR probe suggested specific interactions in the assay
system, while the shallow curve for the mouse IgG1 probe indicated
the small size increase of the nanoparticle probes was due to non-
specific interactions. To further confirm the specificity of anti-
Figure 3. Co-immunoprecipitation with immunoblotting analysis of the effects of modulation of EGFR, Src and Stat3 on the nuclear
EGFR, Src and Stat3 complex. (A, B, and C) Immunoblotting analyses of immunecomplexes of Stat3 (IP:Stat3), EGFR (IP:EGFR), or Src (IP:Src)
prepared from nuclear extracts of Panc-1 cells untransfected or transfected with Src siRNA, EGFR siRNA, or control (con) siRNA (A), or treated with or
without the EGFR inhibitor (ZD1839, ZD), Src inhibitor (Dasatinib, Das), or the Stat3 inhibitor (S3I-201) for 1 or 24 h (B), or from nuclear extracts pre-
incubated for 2 h with or without 100 mM pY1068, pY1086, or SPI peptide (C) and probing for EGFR, Src, Stat3; or (D) immunoblotting analysis of
nuclear extracts prepared from Panc-1 cells treated or untreated with phenylarsine oxide (PAO) and probing for Src, Stat3, EGFR. Bands corresponding
to proteins in gel are shown; input: except where indicated, represents the immunoblotting for the respective immunoprecipitated protein in the
same amount of lysate or nuclear extract used in the assay; Data are representative of 3 independent studies.
doi:10.1371/journal.pone.0019605.g003
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EGFR-GNP probe in the detection of EGFR from nuclear extract,
an inhibition experiment was conducted in which the extract was
first treated with the monoclonal anti-EGFR antibody. It is
expected that the binding between the monoclonal antibody and
the EGFR protein from the sample will block the subsequent
binding of EGFR (in the sample) to the GNP immunoprobes,
therefore, leading to decreased nanoparticle size increase during the
kinetic assay. Data shown in Figure 4A(ii) confirmed the inhibitory
effect of the monoclonal anti-EGFR antibody. The magnitude of
this inhibition was correlated to the sample treatment time: the 24-
min-treatment inhibited the particle size increase in the assay
stronger than the 7 min-treatment (Fig. 4A(ii)).
After using the anti-EGFR-GNP probe to ‘‘catch’’ the EGFR
protein or protein complex from the nuclear extract sample, a second
polyclonal antibody (anti-Stat3, anti-Src, or anti-EGFR antibody, or
non-specific rabbit polyclonal IgG) was then added to the assay
solution to identify the binding partner of the complex. In negative
control studies using the mouse IgG1-GNP probe, particle size
remains nearly unchanged after the addition of the four polyclonal
antibodies (Fig. 4B(i)). This result confirmed the kinetic binding study
that the non-specific mouse IgG1-GNP probe did not bind with the
EGFR protein or protein complex from the sample. The addition of a
polyclonal antibody itself to the assay solution did not cause significant
nanoparticle size change. By contrast, with the anti-EGFR-GNP
probe, significant particle size increase was observed when anti-Stat3
or anti-Src antibody was added to the assay solution (Fig. 4B(ii), anti-
Stat3, Src). A smaller size increase was observed from anti-EGFR
antibody (Fig. 4B(ii), anti-EGFR) and the rabbit IgG (Fig. 4B(ii), IgG).
Per the assay principle (see Fig. S2), the substantial particle size
increases observed from the addition of anti-Stat3 or anti-Src antibody
to the assay solution can only be explained by the presence of EGFR
in complex with Stat3 and Src in the nuclear extract. EGFR was
specifically bound to the nanoparticle immunoprobes, bringing along
the Stat3 and Src proteins to the nanoparticle surface, and the
subsequent incubation of this assay solution with anti-Stat3 or anti-Src
antibody led to further increase of the nanoparticle size. Furthermore,
it appears that there is an equal amount of Stat3 and Src proteins in
the EGFR, Src, and Stat3 complex. In multiple assays conducted so
far, the size increase caused by anti-Src antibody is always just slightly
lower than the case of anti-Stat3 antibody. Src is a smaller protein
(60 KDa) than Stat3 (89–90 KDa). Therefore, with the binding of the
same amount of antibody to the protein complex-GNP conjugates, the
particle size should be just slightly smaller in the case of anti-Src assay
solution than anti-Stat3 assay solution.
Compared to anti-Stat3 or anti-Src antibody, the particle size
increase upon addition of anti-EGFR antibody to the assay solution
is much smaller, only slightly higher than the non-specific rabbit
IgG. This is explained by the fact that Stat3 and Src are located on
the surface of the nanoparticle-bound EGFR protein, therefore,
block the binding of anti-EGFR antibody to the bound EGFR
proteins. The effectiveness of polyclonal anti-EGFR antibody with
the EGFR protein in the sample was confirmed in a different
Figure 4. Studies of protein complex and protein binding partners using the Detection and Analysis through Nanoparticle Sizing
technology. (A) Kinetic binding assay of EGFR-gold nanoparticle (GNP) probe (or mouse IgG1-GNP probe as negative control) binding to (i) EGFR
protein and its complex from Panc-1 nuclear extracts, and the (ii) inhibitory effect of the mouse monoclonal anti-EGFR antibody on the EGFR-GNP
probe binding to the EGFR protein; and (B) Protein complex binding partner analysis whereby the polyclonal anti-Stat3, anti-Src or anti-EGFR
antibody or the non-specific rabbit IgG (negative control) is added to the assay solution prepared from the (i) non-specific mouse IgG1-GNP probe
(negative control), or (ii) anti-EGFR-GNP probe; Data are representative of 4 independent studies.
doi:10.1371/journal.pone.0019605.g004
A Functional Nuclear EGFR, Src and Stat3 Complex
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19605
experiment (data not shown). This result indirectly suggested that
the EGFR protein detected by the nanoparticle immunoprobe from
the nuclear extract exists as a complex with Stat3 and Src protein.
Detection of EGFR, Src and Stat3 heterocomplex by
immunofluorescence with laser-scanning confocal
microscopy
Immunofluorescence with laser-scanning confocal microscopy
allowed visualization of the intracellular distribution and localiza-
tion patterns of EGFR, Src and Stat3. Immunofluorescence with
laser-scanning confocal microscopy confirmed the localization
patterns and showed that in contrast to the negative staining
(Fig. 5B(i), left panel), EGFR appearance is punctuate (red) at the
plasma membrane, and in the cytoplasm and the nucleus
(Fig. 5B(i), single). Similar localizations for Src (blue) and Stat3
(green) were observed, but with greater presence in the nucleus
(Fig. 5B(i), single). There are stainings for colocalization of EGFR
and Src (magenta, see arrows), EGFR and Stat3 (yellow, see
arrows), Src and Stat3 (cyan, see arrows), and of all three entities
(pale yellow/white, see white arrows) at the plasma membrane,
cytoplasm, perinuclear and nuclear spaces (Fig. 5B(i), merge).
Figure 5. Immunofluorescence with laser-scanning confocal microscopy of EGFR, Src and Stat3 association in HPDEC or Panc-1
cells. Cultured normal human pancreatic duct epithelial cells (HPDEC) (A) or pancreatic cancer, Panc-1 cells (B) were fixed, stained with primary
antibodies against EGFR, Src and Stat3 and their corresponding secondary antibodies, ALexaFLuor405 (goat anti-mouse, EGFR, red), AlexaFluor488
(donkey anti-rabbit, Src, blue) and AlexaFluor546 (goat anti-rat, Stat3, green) and analyzed by laser-scanning confocal microscopy for localization
(single) and colocalization (merge) studies of EGFR (red), Src (blue) and Stat3 (green) and the effects of treatment (i) without or (ii) with ZD1839 (ZD)
or (iii) Dasatinib (Das) for the indicated times. Confocal images were collected using Leica TCS SP5 microscopes; Cyan, magenta, yellow and white/
pale yellow arrows denote merged colors; single, one color capture, merged, three-color capture. Data are representative of 3 independent studies.
doi:10.1371/journal.pone.0019605.g005
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These studies confirm previous reports of the association of EGFR
and Stat3 in similar intracellular spaces [6,10]. Importantly, the
data show for the first time the presence of a heteromeric EGFR,
Src and Stat3 complex in the nucleus, as observed by the co-IP and
immunoblotting analyses, and confirmed by DANS/DLS analysis.
These data contrast the results observed for the normal human
pancreatic duct epithelial cells (HPDEC) (Fig. 5A). Immunofluo-
rescence staining with laser-scanning confocal microscopy analysis
of HPDEC shows a homogeneous distribution of EGFR (red), Src
(blue) and Stat3 (green), all of which are strongly outside of the
nucleus, with little evidence of co-localization (Fig. 5A).
Visualization of the intracellular distribution patterns of EGFR,
Src and Stat3 upon inhibition of EGFR or Src tyrosine kinase by
immunofluorescence with laser-scanning confocal microscopy
indicated that as with the co-IP studies (Fig. 3B), the inhibition
of Src or EGFR tyrosine kinase activity alone did not completely
eliminate the complex formation. However, Src or EGFR
inhibition disrupted the localization patterns. Data shows EGFR,
Src and Stat3 distribution in the cytoplasm and the nucleus
following 1- or 24-h treatment with EGFR or Src inhibitor
(Fig. 5B(ii) and (iii), 1 h, and 24 h, single). Nuclear EGFR levels
are diminished, but not abolished (Fig. 5B(ii), single). Thus, EGFR,
Src and Stat3 remain localized in the nucleus following tyrosine
kinase inhibition. Results further showed persistent EGFR and Src
(magenta), and Src and Stat3 (cyan) associations in both the
nucleus and cytoplasm following treatment for 1 h with EGFR or
Src inhibitor (Fig. 5B(ii) and (iii), 1 h), similar to the data in
Figure 3B (1 h). Furthermore, a nuclear EGFR and Stat3
association (yellow) is detected upon 24-h treatment with the
EGFR inhibitor (Fig. 5B(ii), 100 nM ZD, 24 h), while nuclear
associations of EGFR and Src (magenta), and of Src and Stat3
(cyan) are detected following treatment with Src inhibitor for 24 h
(Fig. 5B(iii), 100 nM Das, 24 h). The moderate differences in the
observed patterns of complex formation between the co-IP
(Fig. 3B) and confocal data may be due to the sensitivity
differences between the two approaches. Overall, the findings
are consistent with the co-IP data (Fig. 3B) in showing that the
inhibition of the kinase activity of EGFR or Src alone is insufficient
to completely disrupt all the proteins from the complex.
EGFR, Src and Stat3 heteromeric complex regulates the
c-Myc gene expression
In our previous work, we showed that pancreatic cancer cells were
insensitive to the inhibition of EGFR, Src or Stat3 activity alone, in
parallel with the observation that the expression of c-Myc was also
refractory to the inhibition of EGFR, Src or Stat3 alone, while the
concurrent inhibition of aberrant Stat3 activity together with EGFR
or Src inhibition strongly suppressed c-Myc expression and induced
stronger antitumor cell effects [16]. Those findings suggest a complex
regulation of c-Myc induction, which might support the cancer
phenotype. Previous report identified only that the nuclear EGFR
and Stat3 complex in breast cancer cells induced specific genes,
including inducible nitric oxide synthase (iNOS) [10]. Studies were
performed to assess the functional significance of the heteromeric
complex, particularly in the context of the induction of the c-Myc
gene in pancreatic cancer cells. Chromatin immunoprecipitation
(ChIP) analysis was pursued to assess the association of the c-Myc
promoter with the heteromeric complex. PCR amplification of DNA
fragment using a primer against the c-Myc gene promoter and
agarose gel electrophoresis showed that each of the anti- EGFR, Src,
or Stat3 antibody-chromatin DNA immunoprecipitate contained
the c-Myc gene (Fig. 6A(i), EGFR, Src and Stat3). To further
confirm this finding, we pursued a modified sequential immunopre-
cipitation analysis similar to the one performed in Figure 2B in the
context of a ChIP assay, as previously reported [10]. In the
sequential ChIP assay in which EGFR chromatin immunecomplex
was subjected to a second immunoprecipitation using anti-Src
antibody and analyzed by PCR amplification and agarose gel
electophoresis, we similarly detected the presence of the c-Myc gene
Figure 6. Chromatin immunoprecipitation assay and Western
blotting analysis of c-Myc, iNOS, Cyclin D1, and VEGF expres-
sion in Panc-1 and Colo-357 cells. (A), Agarose gel electrophoresis of
the Polymerase Chain Reaction (PCR)-amplified c-Myc gene fragment
from the chromatin DNA precipitated with antibody against EGFR, Src, or
Stat3, or with the non-specific IgG; and (B and C), Immunoblotting
analysis of whole-cell lysates probing for EGFR or Src (B(i) and C(i)) or c-
Myc, iNOS, Cyclin D1 or VEGF (B(ii) and C(ii)), and the effects of siRNA
knockdown of EGFR (EGFR siRNA), Src (Src siRNA) or control (con) siRNA,
or S3I-201 or Das). Bands corresponding to proteins or c-Myc gene in gel
are shown; M, molecular weight marker, EGFR/Src, sequential immuno-
precipitation with anti-EGFR and then anti-Src antibody. Data are
representative of 3 independent studies, and values are mean and s.d
of 3 independent studies; *p-,0.01.
doi:10.1371/journal.pone.0019605.g006
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(Fig. 6A(ii), EGFR/Src). By contrast, PCR analysis showed no
appreciable detection of TWIST, a gene previously reported to be
EGFR target [22] in the EGFR chromatin immunecomplex, while
the gene was detected in the Stat3 and Src chromatin-immunopre-
cipitates (Fig. S3). These differences may be tumor cell-type
dependent. To verify the specificity of the immunoreagents, the
non-specific IgG was similarly used in the ChIP assay, and
subsequent PCR analysis showed no detectable levels of the c-Myc
gene (Fig. 6A, IgG). Taken together with the sequential immuno-
precipitation data in Figure 2B), these studies demonstrate that
EGFR, Src and Stat3 form a detectable heteromeric complex that is
associated with the expression of c-myc in pancreatic cancer cells.
To further study the potential involvement of the heteromeric
EGFR, Src and Stat3 complex in the regulation of genes, we
performed immunoblotting analysis of known regulated genes,
including c-Myc. Results showed moderate or no significant
change in the expression of c-Myc, Cyclin D1, iNOS, and VEGF
upon the siRNA knockdown of EGFR or Src alone (Fig. 6B). By
contrast, the concurrent knockdown of EGFR with Stat3
inhibition (by S3I-201) [25], or the concurrent knockdown of
Src with Stat3 inhibition, or the concurrent EGFR knockdown
with Src inhibition (by Das) resulted in a strong suppression of c-
Myc expression (Fig. 6C(ii)). The bands corresponding to the
expression levels of c-Myc were quantified, analyzed by Im-
ageQuant, and represented as percent of control (Fig. 6C(ii), %
numbers in parenthesis). Results show over 76% suppression of c-
Myc expression (Fig. 6C(ii)) following the concurrent modulation
of any two of EGFR, Src and Stat3, except for the siRNA
knockdown of EGFR and Src together, which only showed 20%
decrease. The moderate change in the c-Myc expression in
response to the co-transfection with EGFR siRNA and c-Src
siRNA may be due to the fact that we could only achieve partial
knockdown of Src (Fig. 6C(i)), although EGFR is significantly
suppressed by the EGFR siRNA (Fig. 6C(i)). In contrast, the use of
the pharmacological inhibitor, Das, which strongly inhibits Src
activity, in combination with siRNA knockdown of EGFR strongly
suppressed c-Myc expression. These studies together suggest the
possibility that the c-Myc gene is regulated by EGFR, Src and
Stat3 complex in a manner that is susceptible to concurrent
modulation of any two of the EGFR, Src and Stat3 proteins, but
not to the inhibition of EGFR, Src or Stat3 alone.
Discussion
Aberrations in the EGFR, c-Src and Stat3 signaling pathways
occur with a high frequency in many human cancers
[14,15,38,39,40,41] and are associated with poor prognosis.
Notably, constitutively-active Stat3 induces dysregulation of gene
expression, contributing to the altered gene expression profile that
is a hallmark of cancer. The details of aberrantly-active Stat3-
mediated dysregulation of gene expression continue to be
elucidated and the initial studies indicate the mechanisms are
more complex. The present studies strongly suggest that in
forming a nuclear, transcriptionally-active EGFR, Src, Stat3
heteromeric complex, the EGFR and Src proteins cooperate with
Stat3 to promote the altered gene expression. Such cooperation
between Stat3 and other proteins for the transcriptional induction
of genes has similarly been observed in other systems. Specifically,
Stat3 cooperates with NF-kB to induce certain genes [42,43].
Furthermore, there have been reports of a nuclear EGFR pathway
[8,9], in which a nuclear EGFR-Stat3 complex promotes the
induction of iNOS in breast cancer cells [10]. These reports
together with our present findings indicate the complicated nature
of the mechanisms by which aberrantly-active Stat3 might
dysregulate gene expression in cancer cells. In this context, the
present studies extend our earlier report [16] in suggesting that
nuclear heteromeric EGFR, Src and Stat3 complex regulates the
c-Myc gene in pancreatic cancer cells. It is likely that other genes
may by induced by the EGFR, Src and Stat3 nuclear complex and
we note that iNOS, VEGF, and Cyclin D1 are reported to be
induced by the EGFR/Stat3 complex or Stat3 [10,44,45] and
could well be candidates for the regulation by the EGFR, Src and
Stat3 complex. Taken together, these studies provide a novel
mechanism for the de-regulation of gene expression in cancer cells.
The observation that the EGFR, Src and Stat3 complex is also
detected in the cytoplasm raises the possibility that it is formed
extra-nuclear and transported into the nuclear space. Previous
reports have described inherent EGFR nuclear localization
mechanisms, including facilitation via the endosomal sorting
machinery and the interaction with importins a1/b1 [31], and
several nuclear translocation mechanisms have also been proposed
for Stat3, including EGFR-mediated endocytosis [6,31]. Although
any of these processes could facilitate the nuclear translocation of
the heteromeric EGFR, Src, Stat3 complex should it be formed
outside of the nucleus, the present data excludes the possibility that
EGFR-mediated endocytosis is involved. Whether the other
nuclear translocation pathways proposed for Stat3, including the
utilization of the Ran-GTPase [4], Sec61 translocon [46], and
chaperoning by MgcRacGAP [5] are involved in promoting the
nuclear transport of the complex remains to be studied. Our
findings also do not preclude the assembly of the complex de novo in
the nucleus. Present data also suggest that only a portion of the
intracellular EGFR, Src and Stat3 protein pools are utilized in the
formation of the nuclear complex, raising the possibility that there
may be diverse cellular pools of EGFR, Src, or Stat3 with different
accessibility limitations. There also could be different pools of pre-
associated complexes of the three proteins, a possibility that will be
consistent with the report that cytoplasmic Stat3 exists as
complexes with accessory scaffolding proteins [47]. Such pre-
formed complexes would not only facilitate the signal induction
[48], but may also serve to stabilize the proteins.
The incidence of signaling cross-talk has long been known, and
the associations of EGFR with Src [49], Src with Stat3 [20,50], and
EGFR with Stat3 [26,27] at the plasma membrane and the
perinuclear space [6] have been reported. Specifically, Stat3 binds
to pY1068 and pY1086 motifs of EGFR [26,27], while Src binds to
Y845EGFR. In cancer cells, aberrant Stat3 activation is promoted
by hyperactive protein tyrosine kinases, including EGFR and Src
[15,40,41], and evidence has indicated that c-Src phosphorylates
Y845EGFR, Y1068EGFR, and Y845EGFR motifs in pancreatic
cancer cells [16,27,51]. Present data reveals that the pY1068EGFR
and pY1086EGFR motifs and the Stat3 SH2 domain amino acid
residues 588–615 are essential for EGFR-Stat3 interaction within
the context of the heteromeric EGFR, Src and Stat3 complex. It
remains to be determined what the exact configuration is for the
heteromeric complex. Also, the present data does not exclude the
possibility that other accessory proteins could be present in the
complex together with EGFR, Src and Stat3.
We had recently reported about the functional cooperation
between EGFR, Src and Stat3 in promoting and supporting
pancreatic cancer, wherein the cancer phenotype and the
expression of c-Myc in the cancer cells were both insensitive to
the inhibition of EGFR, Src or Stat3 alone [16]. While it is
possible that the c-Myc gene may be regulated cooperatively by
EGFR, Src and Stat3 through mechanisms independent of each
other, our study also raises the possibility of a complex
transcriptional regulation by mechanisms that involve the nuclear
EGFR, Src and Stat3 heteromeric complex.
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Supporting Information
Text S1 Detail description of Dynamic Light Scattering
(DLS).
(DOC)
Figure S1 Immunoblotting analysis of EGFR, Src, Stat3,
and RHA from Panc-1, MDA-MB-231, or A549 cells.
Immunoblotting analysis of (A and B) fractions collected from gel
filtration chromatographic analysis of Panc-1 cell lysates probing for
EGFR, Src, Stat3,or RHA (A), or EGFR immunecomplex from the
pooled fractions 23–27 probing for Stat3, Src or EGFR (B), or (C)
immunecomplexes of EGFR or Stat3 from nuclear extracts of human
breast cancer, MDA-MB-231 or non-small cell lung cancer, A549 cells
probing for EGFR, Stat3 and Src. Bands corresponding to proteins in
gel are shown; Data are representative of 2 independent studies.
(TIF)
Figure S2 The principle of DANS technology (Detection
and Analysis through Nanoparticle Sizing) for protein
complex detection and binding partner analysis.
(TIF)
Figure S3 Chromatin Immunoprecipitation assay of
TWIST expression in Panc-1 cells. Agarose gel electropho-
resis of the Polymerase Chain Reaction (PCR)-amplified TWIST
gene fragment from the chromatin DNA precipitated with
antibody against EGFR, Src, or Stat3, or with the non-specific
IgG; M, molecular weight marker; Data are representative of 2
independent studies.
(TIF)
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